Pfizer grants take non-clinical tack

Share this article:


In a sign of industry's ongoing desire to broaden its CME funding outlook, a couple of programs recently supported by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.

The National Comprehensive Cancer Network (NCCN) said it's using a three-year, $2-million educational Pfizer grant to develop an outcomes-based performance improvement effort. 

The nonprofit is mining databases of 10 facilities, then using the registry data to direct physician educational needs at those member institutions, which include oncology facilities at Boston's Mass General, Philly's Fox Chase and MD Anderson in Texas.

“It's totally different from anything that the large oncology groups have done to this point,” Pfizer's senior director of education, oncology, Brian McGowan, said of the NCCN program. “This is pretty much as practice-based and as performance-driven as any of the educational programs that I've seen in the last two years.” 

Pfizer committed a $300,000 challenge grant to the Joslin Diabetes Center for a CME research project that's designed to analyze different outcomes methods used to measure doctor performance (MM&M June 2011). According to Joslin's executive director of professional education Julie Brown, the center has since been able to raise the second half of the grant from GSK and Lilly. 

Such programs “seem to be received the best and to be a more appropriate place for support to go,” said McGowan.




Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?